Western European Cardiac Troponin Diagnostics Market, Forecast to 2021

Western European Cardiac Troponin Diagnostics Market, Forecast to 2021

Emerging Biomarkers Disrupt and Spur Growth in the Heart Disease Segment

RELEASE DATE
25-May-2018
REGION
Europe
Research Code: PA07-01-00-00-00
SKU: HC03015-EU-MR_21951
$3,000.00
In stock
SKU
HC03015-EU-MR_21951
$3,000.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Cardiac troponins have now become the gold standard for early diagnosis of acute myocardial infarction, making them indispensable for clinical diagnosis of Acute Coronary Syndrome (ACS). Cardiac troponins play a key role in minimizing hospital stays and reducing admission rate which are the biggest contributors to overall healthcare expenditure. For example, in Europe and the US, the total cost of heart failure associated health expenditure is valued at $ 100 billion, of which 70% is due to hospitalization. ECG can detect only one-thirds of patients with persistent ST-segment elevation (STEMI), whereas cardiac troponins can distinguish patients without ST-segment elevation (NSTEACS or non-ST segment elevation ACS) who require a conservative unstable angina (UA) or early-invasive approach (NSTEMI).The advent of new biomarkers (e.g., H-FABP) over high-sensitivity troponins, or in combination, is currently explored for clinical utility and cost-effectiveness.

Cardiovascular diseases (CVD) remain the leading cause of mortality and a major cause of morbidity in Europe. The WEU cardiac diagnostic market is a high-value market, with a consistent increase in demand due to regulatory changes that are set to impact the cardiac diagnostics market across Europe. The objective of this research is to establish an understanding in the segment of cardiac biomarker troponin used for the diagnosis of acute myocardial Infarction. The research covers the revenue generated by the use of cardiac troponin tests for diagnosis of acute myocardial infarction.

Physicians are demanding a more accurate test which could reduce the burden in the healthcare settings. For patients under acute critical conditions (e.g., myocardial infarction), fast results and quick diagnosis are required. Rising prevalence of MI and increasing morbidity in the region will fuel the growth of diagnostic testings. Moreover, demands from physicians for more accurate and sensitive results will push researchers and investments for the diagnosis of MI.

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Key Findings

Scope and Segmentation

Market Engineering Measurements

Key Companies to Watch

Market Background

Cardiac Diagnostics in Western Europe—An Overview

Testing Procedure

Cardiac Troponin Test Guidelines

Cardiac Troponins in Clinical Applications

High-Sensitive Troponins—Use in Clinical Settings

Cardiac Troponins in Clinical Applications

Comparative Analysis of Cardiac Necrosis Markers

Healthcare Trends of the Future

New Market Opportunities

Notable Deals and Launches—Cardiac Biomarker Diagnostics

Market Drivers

Market Restraints

Forecast Methodology

Market Engineering Measurements

Revenue Forecast

Revenue Share by Country

Percent Revenue Breakdown by Segment

Competitive Structure

Market Share

Market Share Analysis

Major Growth Opportunities

Growth Opportunity Matrix

Growth Opportunity 1—Companion Diagnostics

Growth Opportunity 2—POCT in Cardiac Biomarker Diagnostics

Growth Opportunity 3—Integrated and Efficient System

Growth Opportunity 4—Digital Health and Diagnostics Inter-Convergence Model

Strategic Imperative for the Cardiac Troponins Market

Market Engineering Measurements

Revenue Forecast

Segment Share

Segment Share Analysis

Market Engineering Measurements

Revenue Forecast

Segment Share

Segment Share Analysis

The Last Word—3 Big Predictions

Legal Disclaimer

List of Exhibits

List of Others Companies

List of Figures
  • 1. Cardiac Troponin Diagnostics Market: Expression Patterns Across Cardiac Disorders, Western Europe, 2016
  • 2. Total Cardiac Troponin Diagnostics Market: Clinical Applications, Western Europe, 2016
  • 3. Total Cardiac Troponin Diagnostics Market: Comparative Analysis of Cardiac Biomarkers, WEU, 2016
  • 4. Total Cardiac Troponin Diagnostics Market: Market Outlook, Western Europe, 2016 and 2021
  • 5. Total Cardiac Troponin Diagnostics Market: Game-changing Strategies, Western Europe, 2016
  • 6. Total Cardiac Troponin Diagnostics Market: Notable Deals and Launches, Western Europe, 2016–2017
  • 7. Total Cardiac Troponin Diagnostics Market: Key Market Drivers, Western Europe, 2017–2021
  • 8. Total Cardiac Troponin Diagnostics Market: Key Market Restraints, Western Europe, 2017–2021
  • 9. Total Cardiac Troponin Diagnostics Market: Market Engineering Measurements, Western Europe, 2016
  • 10. Total Cardiac Troponin Diagnostics Market: Competitive Structure, Western Europe, 2016
  • 11. Total Cardiac Troponin Diagnostics Market: Company Market Share Analysis of Top Participants, Western Europe, 2016
  • 12. Cardiac Troponins Lab-based Test Segment: Market Engineering Measurements, Western Europe, 2016
  • 13. Cardiac Troponins Lab-based Test Segment: Company Segment Share Analysis of Top Participants, Western Europe, 2016
  • 14. Cardiac Troponins POCT Segment: Market Engineering Measurements, Western Europe, 2016
  • 15. Cardiac Troponins POCT Segment: Company Segment Share Analysis of Top Participants, Western Europe, 2016
List of Charts
  • 1. Total Cardiac Troponin Diagnostics Market: Market Engineering Measurements, Western Europe, 2016
  • 2. Total Cardiac Troponin Diagnostics Market: Market Segmentation, Western Europe, 2016
  • 3. Total Cardiac Troponin Diagnostics Market: Barriers to POCT Adoption, Western Europe, 2016
  • 4. Total Cardiac Troponin Diagnostics Market: Revenue Forecast, Western Europe, 2015–2021
  • 5. Total Cardiac Troponin Diagnostics Market: Revenue Share by Country, Western Europe, 2016
  • 6. Total Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Segment, Western Europe, 2016
  • 7. Total Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Segment, Western Europe, 2021
  • 8. Total Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown, Western Europe, 2016
  • 9. Total Cardiac Troponin Diagnostics Market: Growth Opportunity Matrix, Western Europe, 2016
  • 10. Cardiac Troponins Lab-based Test Segment: Revenue Forecast, WEU, 2015–2021
  • 11. Cardiac Troponins Lab-based Test Segment: Percent Revenue Breakdown, Western Europe, 2016
  • 12. Cardiac Troponins POCT Segment: Revenue Forecast, Western Europe, 2015–2021
  • 13. Cardiac Troponins POCT Segment: Percent Revenue Breakdown, Western Europe, 2016
Related Research
Cardiac troponins have now become the gold standard for early diagnosis of acute myocardial infarction, making them indispensable for clinical diagnosis of Acute Coronary Syndrome (ACS). Cardiac troponins play a key role in minimizing hospital stays and reducing admission rate which are the biggest contributors to overall healthcare expenditure. For example, in Europe and the US, the total cost of heart failure associated health expenditure is valued at $ 100 billion, of which 70% is due to hospitalization. ECG can detect only one-thirds of patients with persistent ST-segment elevation (STEMI), whereas cardiac troponins can distinguish patients without ST-segment elevation (NSTEACS or non-ST segment elevation ACS) who require a conservative unstable angina (UA) or early-invasive approach (NSTEMI).The advent of new biomarkers (e.g., H-FABP) over high-sensitivity troponins, or in combination, is currently explored for clinical utility and cost-effectiveness. Cardiovascular diseases (CVD) remain the leading cause of mortality and a major cause of morbidity in Europe. The WEU cardiac diagnostic market is a high-value market, with a consistent increase in demand due to regulatory changes that are set to impact the cardiac diagnostics market across Europe. The objective of this research is to establish an understanding in the segment of cardiac biomarker troponin used for the diagnosis of acute myocardial Infarction. The research covers the revenue generated by the use of cardiac troponin tests for diagnosis of acute myocardial infarction. Physicians are demanding a more accurate test which could reduce the burden in the healthcare settings. For patients under acute critical conditions (e.g., myocardial infarction), fast results and quick diagnosis are required. Rising prevalence of MI and increasing morbidity in the region will fuel the growth of diagnostic testings. Moreover, demands from physicians for more accurate and sensitive results will push researchers and in
More Information
No Index No
Podcast No
Table of Contents | Executive Summary~ || Key Findings~ || Scope and Segmentation~ || Market Engineering Measurements~ || Key Companies to Watch~ | Market Overview~ || Market Background~ || Cardiac Diagnostics in Western Europe—An Overview~ || Testing Procedure~ || Cardiac Troponin Test Guidelines~ || Cardiac Troponins in Clinical Applications~ || High-Sensitive Troponins—Use in Clinical Settings~ || Cardiac Troponins in Clinical Applications~ || Comparative Analysis of Cardiac Necrosis Markers~ || Healthcare Trends of the Future~ | Competitive Playbook~ || New Market Opportunities~ || Notable Deals and Launches—Cardiac Biomarker Diagnostics~ | Drivers and Restraints~ || Market Drivers~ || Market Restraints~ | Forecasts and Trends~ || Forecast Methodology~ || Market Engineering Measurements~ || Revenue Forecast~ || Revenue Share by Country~ || Percent Revenue Breakdown by Segment~ | Competitive Environment~ || Competitive Structure~ || Market Share~ || Market Share Analysis~ | Growth Opportunities and Companies to Action~ || Major Growth Opportunities~ || Growth Opportunity Matrix~ || Growth Opportunity 1—Companion Diagnostics~ || Growth Opportunity 2—POCT in Cardiac Biomarker Diagnostics~ || Growth Opportunity 3—Integrated and Efficient System~ || Growth Opportunity 4—Digital Health and Diagnostics Inter-Convergence Model~ || Strategic Imperative for the Cardiac Troponins Market~ | Lab-based Test Segment Analysis~ || Market Engineering Measurements~ || Revenue Forecast~ || Segment Share~ || Segment Share Analysis~ | POCT Segment Analysis~ || Market Engineering Measurements~ || Revenue Forecast~ || Segment Share~ || Segment Share Analysis~ | The Last Word~ || The Last Word—3 Big Predictions~ || Legal Disclaimer~ | Appendix~ || List of Exhibits~ || List of Others Companies~ | The Frost & Sullivan Story~
List of Charts and Figures 1. Cardiac Troponin Diagnostics Market: Expression Patterns Across Cardiac Disorders, Western Europe, 2016~ 2. Total Cardiac Troponin Diagnostics Market: Clinical Applications, Western Europe, 2016~ 3. Total Cardiac Troponin Diagnostics Market: Comparative Analysis of Cardiac Biomarkers, WEU, 2016~ 4. Total Cardiac Troponin Diagnostics Market: Market Outlook, Western Europe, 2016 and 2021~ 5. Total Cardiac Troponin Diagnostics Market: Game-changing Strategies, Western Europe, 2016~ 6. Total Cardiac Troponin Diagnostics Market: Notable Deals and Launches, Western Europe, 2016–2017~ 7. Total Cardiac Troponin Diagnostics Market: Key Market Drivers, Western Europe, 2017–2021~ 8. Total Cardiac Troponin Diagnostics Market: Key Market Restraints, Western Europe, 2017–2021~ 9. Total Cardiac Troponin Diagnostics Market: Market Engineering Measurements, Western Europe, 2016~ 10. Total Cardiac Troponin Diagnostics Market: Competitive Structure, Western Europe, 2016 ~ 11. Total Cardiac Troponin Diagnostics Market: Company Market Share Analysis of Top Participants, Western Europe, 2016~ 12. Cardiac Troponins Lab-based Test Segment: Market Engineering Measurements, Western Europe, 2016~ 13. Cardiac Troponins Lab-based Test Segment: Company Segment Share Analysis of Top Participants, Western Europe, 2016~ 14. Cardiac Troponins POCT Segment: Market Engineering Measurements, Western Europe, 2016~ 15. Cardiac Troponins POCT Segment: Company Segment Share Analysis of Top Participants, Western Europe, 2016~| 1. Total Cardiac Troponin Diagnostics Market: Market Engineering Measurements, Western Europe, 2016~ 2. Total Cardiac Troponin Diagnostics Market: Market Segmentation, Western Europe, 2016~ 3. Total Cardiac Troponin Diagnostics Market: Barriers to POCT Adoption, Western Europe, 2016~ 4. Total Cardiac Troponin Diagnostics Market: Revenue Forecast, Western Europe, 2015–2021~ 5. Total Cardiac Troponin Diagnostics Market: Revenue Share by Country, Western Europe, 2016~ 6. Total Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Segment, Western Europe, 2016~ 7. Total Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Segment, Western Europe, 2021~ 8. Total Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown, Western Europe, 2016~ 9. Total Cardiac Troponin Diagnostics Market: Growth Opportunity Matrix, Western Europe, 2016~ 10. Cardiac Troponins Lab-based Test Segment: Revenue Forecast, WEU, 2015–2021~ 11. Cardiac Troponins Lab-based Test Segment: Percent Revenue Breakdown, Western Europe, 2016~ 12. Cardiac Troponins POCT Segment: Revenue Forecast, Western Europe, 2015–2021~ 13. Cardiac Troponins POCT Segment: Percent Revenue Breakdown, Western Europe, 2016~
Author Sanjeev Kumar
Industries Healthcare
WIP Number PA07-01-00-00-00
Keyword 1 Cardiac Troponin
Is Prebook No
GPS Codes 9571-B1,9573-B1,9600-B1,9611-B1,9627-B1,9888-B1,9A42-B1,9A43-B1